MKI67 and meningioma: The main directions of application were breast cancer (ER/PR receptors), tumours of the nervous system (neuroblastoma, meningioma, oligodendroglioma – Ki-67 staining) and gastric inflammatory (chromogranin, serotonin and somatostatin antibodies).